Clinical trials: Estrogen
Skin Wrinkling
Mechanisms of Skin Repair by Topical Estrogen
The purpose of this study is to investigate the way by which estrogen improves the appearance of sun damaged human skin. Accumulating evidence suggests that estrogen, taken by post menopausal women, may cause skin to look younger…
- Trial name
- NCT00113100
- Testing
- Topical 17-beta estradiol in ethanol/propylene glycol (ETOH/PG)
- Where
- United States
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Advanced and Metastatic Breast Cancer
Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer
This dose finding/extension study was designed originally to consist of three parts: Part A was intended to identify the MTD of the AZD2014/ palbociclib combination on a background of fulvestrant (referred to as the triplet) in…
- Trial name
- PASTOR (NCT02599714)
- Testing
- AZD2014, Palbociclib, Fulvestrant
- Where
- 7 sites in United States, United Kingdom
- Volunteers
- 54 people
- Sponsor
- AstraZeneca
Estrogen Profile
The Effects of EstroSense®/MD vs Placebo in Improving the Estrogen Profile in Females
According to the Canadian Cancer Society, 1 in 9 Canadian women will develop breast cancer in her lifetime and 1 in 30 will die. The single greatest risk factor of breast cancer is poor estrogen metabolism.
- Trial name
- NCT02385916
- Testing
- EstroSense®/MD
- Where
- Canada
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Advanced Breast Cancer
Study of Zoladex Given Every 12 Weeks Versus Given Every Month in Advanced Breast Cancer (ABC) Pre-menopausal Women
The primary objective is to evaluate whether Zoladex 10.8 mg (12-weekly) is non-inferior to Zoladex 3.6 mg (4-weekly) in pre-menopausal women with oestrogen receptor positive advanced breast cancer by assessment of…
- Trial name
- NCT00322348
- Testing
- Goserelin acetate
- Where
- 14 sites in Czechia, Russia and 1 more
- Volunteers
- 98 people
- Sponsor
- AstraZeneca
Gender Dysphoria
Comparison of PKs of 17-Beta-Estradiol Via Sublingual Placement Versus Swallowing in Male-to-Female Transgender Patients
This crossover study will investigate the pharmacokinetics of oral versus sublingual administration of 17-beta-estradiol in the trans-female population.
- Trial name
- NCT05428215
- Testing
- 17beta Estradiol
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- MaineHealth
Breast Cancer
Positive ER Expression Assessed by 18F-FES PET/CT in the MBC with ER-negative Primary Tumor
To investigate the treatment pattern and efficacy of patients with negative primary ER lesion but positive ER expression in MBC using a novel convenient way of 18F-fluoroestradiol positron emission tomography/computed tomography…
- Trial name
- NCT06344767
- Where
- China
- Volunteers
- 19 people
- Sponsor
- Fudan University
Genitourinary Syndrome of Menopause
Efficacy of the Use of Cellular Matrix/ A-CP-HA Kit
This study is a randomized, controlled, non-inferiority trial, that will be performed on 192 women on Menopause (absence of menstruation for at least 12 months), with diagnostic of genitourinary syndrome of menopause (SGM) and a…
- Trial name
- CellularMatrix (NCT06425978)
- Testing
- Cellular Matrix / A-CP-HA Kit, Local estrogen therapy (Blissel, estriol 50 micrograms/g vaginal gel)
- Where
- Spain
- Volunteers
- 192 people
- Sponsor
- Fundación Santiago Dexeus Font
Breast Cancer, Hot Flashes
Reproductive Health Survivorship Care Plan Pilot
Most young breast cancer patients undergo chemotherapy and/or endocrine therapy, treatments that impair ovarian function and result in significant reproductive health late effects.
- Conditions
- Breast Cancer, Hot Flashes, Vaginal Dryness, Estrogen Deprivation Symptoms
- Trial name
- NCT02176083
- Testing
- Text message management prompts
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- University of California, San Diego
Obesity
Prevention of Obesity in Women Via Estradiol Regulation
The purpose of this study is to evaluate potential mechanisms by which estradiol deficiency accelerates fat gain and abdominal fat accumulation in women.
- Trial name
- POWER (NCT00687739)
- Testing
- leuprolide acetate, Estradiol Transdermal, progressive resistance exercise training
- Where
- United States
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Estrogen Receptor Positive, HER2/Neu Negative
Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer
This randomized phase II trial studies the side effects and how well fulvestrant and palbociclib with or without copanlisib work in treating patients with hormone receptor positive, HER2 negative, stage IV breast cancer.
- Conditions
- Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive, Stage IV Breast Cancer AJCC v6 and v7
- Trial name
- NCT03377101
- Testing
- Copanlisib, Fulvestrant, Laboratory Biomarker Analysis
- Sponsor
- National Cancer Institute (NCI)
Hypoactive Sexual Desire Disorder
A Pharmacokinetic (PK) Study to Compare the Absorption of Two Formulations of Transdermal Testosterone Spray and Intrinsa®
The purpose of this study is to determine if the absorption of the testosterone spray is the same as the Intrinsa® Patch.
- Trial name
- NCT01096329
- Testing
- Testosterone Spray 5% and 1%, Intrinsa® Patch and Testosterone Spray 5%, Intrinsa® Patch and Testosterone Spray 1%
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- VIVUS LLC
Breast Neoplasms, Osteoporosis
Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy
This protocol is designed to compare the effect on bone of Zoledronic Acid 4 mg every 6 months when given upfront versus delayed start (based on a post-baseline BMD T- Score below -2.0 SD at either the lumbar spine or total hip…
- Trial name
- NCT00050011
- Testing
- Zoledronic Acid, Letrozole
- Where
- 44 sites in United States, Puerto Rico
- Volunteers
- 602 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma
Elacestrant With Everolimus for the Treatment of Recurrent Advanced or Metastatic ER-Positive Endometrial Cancer
This phase II trial tests how well elacestrant with everolimus works for the treatment of estrogen receptor (ER) positive endometrial cancer that has come back after a period of improvement (recurrent), that may have spread from…
- Conditions
- Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma, Recurrent Endometrial Carcinoma, Stage III Endometrial Cancer
- Trial name
- NCT07634601
- Testing
- Biospecimen Collection, Computed Tomography, Elacestrant
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Carcinoma, Ovarian Epithelial, Low Grade Serous Adenocarcinoma of Ovary
Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer (LEPRE Trial)
This is an Italian, multicenter, randomized, open-label phase III trial which will evaluate if Letrozole is superior to standard adjuvant chemotherapy in patients with hormone receptor positive low-grade serous epithelial…
- Trial name
- LEPRE (NCT05601700)
- Testing
- Letrozole tablets, carboplatin AUC 5 and paclitaxel 175 mg/m2
- Where
- 19 sites in Italy
- Volunteers
- 132 people
- Sponsor
- Ente Ospedaliero Ospedali Galliera
Obesity, Glucose Homeostasis
Bazedoxifene/Conjugated Estrogens (BZA/CE) Improvement of Metabolism (BIM)
The goal of this pilot clinical study is to perform a randomized placebo-controlled study to assess the beneficial effect of a 3 month-treatment with Bazedoxifene/Conjugated Estrogens (BZA/CE) vs.
- Conditions
- Obesity, Glucose Homeostasis, Postmenopausal Symptoms
- Trial name
- BIM (NCT02237079)
- Testing
- Bazedoxifene/Conjugated Estrogens (BZA/CE)
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Tulane University Health Sciences Center
Breast Cancer
A Study of AC682 In Chinese Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer
This clinical trial is evaluating AC682 in participants with estrogen receptor positive/human epidermal growth factor 2 negative (ER+/HER2-) locally advanced or metastatic breast cancer. The main goals of this study are to: 1.
- Trial name
- NCT05489679
- Testing
- AC682
- Where
- 3 sites in China
- Volunteers
- 6 people
- Sponsor
- Accutar Biotechnology Inc
Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy
This phase II trial studies how well atorvastatin works in treating patients with stages IIb-III triple negative breast cancer who did not achieve a pathologic complete response to neoadjuvant chemotherapy.
- Conditions
- Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8
- Trial name
- NCT03872388
- Testing
- Atorvastatin, Capecitabine
- Where
- 5 sites in United States
- Volunteers
- 6 people
- Sponsor
- M.D. Anderson Cancer Center
ER+ HER2- Advanced Breast Cancer
AZD9496 First Time in Patients Ascending Dose Study
This is a phase 1 open label multicentre study of AZD9496 administered orally in patients with advanced ER+ HER2 negative breast cancer.
- Trial name
- NCT02248090
- Testing
- AZD9496
- Where
- 6 sites in United States, South Korea and 1 more
- Volunteers
- 45 people
- Sponsor
- AstraZeneca
Breast Cancer
Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer
This is a multicenter, Phase 1b-2 study of elacestrant in combination with onapristone in patients with advanced/metastatic ER+/PgR+/HER2- breast cancer.
- Trial name
- ELONA (NCT05618613)
- Testing
- Elacestrant, Onapristone
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Context Therapeutics Inc.
Vaginal Dryness, Breast Cancer
Vaginal DHEA for Women After Breast Cancer
There does not appear to be a consensus regarding the treatment of vaginal dryness in women who have a contraindication to the use of estrogen products.
- Conditions
- Vaginal Dryness, Breast Cancer, Urinary Incontinence, Quality of Life
- Trial name
- NCT01724242
- Testing
- Vaginal DHEA
- Where
- Israel
- Sponsor
- Hadassah Medical Organization
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.